Dihydropyrimidine dehydrogenase gene as a major predictor of severe 5-fluorouracil toxicity

Pharmacogenomics

Volumn 12, Issue 9, 2011, Pages 1321-1336

  Amstutz, Ursula ^a,b   Froehlich, Tanja K ^a   Largiadr, Carlo R ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

5 fluorouracil; capecitabine; dihydropyrimidine dehydrogenase; DPYD; gene polymorphism; toxicity

Indexed keywords

ADENINE; BEVACIZUMAB; CAPECITABINE; CYTOSINE; DRUG METABOLITE; FLUOROURACIL; FOLINIC ACID; GUANINE; IRINOTECAN; OXALIPLATIN; PLATINUM COMPLEX; THYMINE;

ADVERSE DRUG REACTION; ALOPECIA; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CATABOLISM; COLORECTAL CARCINOMA; DIARRHEA; DIGESTIVE SYSTEM CANCER; DIHYDROPYRIMIDINE DEHYDROGENASE GENE; DISEASE SEVERITY; DNA METHYLATION; DNA POLYMORPHISM; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DEGRADATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG WITHDRAWAL; GENE; GENE FREQUENCY; GENE MUTATION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; GENOTYPE PHENOTYPE CORRELATION; HAND FOOT SYNDROME; HAPLOTYPE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; LEUKOENCEPHALOPATHY; LOW DRUG DOSE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NONHUMAN; NUCLEOTIDE SEQUENCE; PHARMACOGENETICS; POPULATION GENETICS; PREDICTION; PROMOTER REGION; REVIEW; RISK ASSESSMENT; RNA SPLICING; STOMATITIS; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC AGENTS; DEOXYCYTIDINE; DIHYDROURACIL DEHYDROGENASE (NADP); FLUOROURACIL; GENETIC ASSOCIATION STUDIES; GENOTYPE; HALF-LIFE; HUMANS; INTRONS; MUTATION; POLYMORPHISM, SINGLE NUCLEOTIDE; RNA SPLICE SITES;

EID: 80052944892     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.11.72     Document Type: Review

References (83)

1. Meyerhardt JA, Mayer RJ. Systemic therapy for colorectal cancer. N. Engl. J. Med. 352(5), 476-487 (2005).
2. Mattison LK, Soong R, Diasio RB. Implications of dihydropyrimidine dehydrogenase on 5-fuorouracil pharmacogenetics and pharmacogenomics. Pharmacogenomics 3(4), 485-492 (2002). (Pubitemid 34814677)
3. Diasio RB, Harris BE. Clinical pharmacology of 5-fuorouracil. Clin. Pharmacokinet. 16, 215-237 (1989).
4. Ezzeldin H, Diasio R. Dihydropyrimidine dehydrogenase defciency, a pharmacogenetic syndrome associated with potentially life-threatening toxicity following 5-fuorouracil administration. Clin. Col. Cancer 4(3), 181-189 (2004).
5. Van Kuilenburg AB, Maring JG, Schalhorn A et al. Pharmacokinetics of 5-fuorouracil in patients heterozygous for the IVS14+1G > A mutation in the dihydropyrimidine dehydrogenase gene. Nucleosides Nucleotides Nucleic Acids 27(6), 692-698 (2008). (Pubitemid 351948568)
6. Milano G, Mcleod HL. Can dihydropyrimidine dehydrogenase impact 5-fuorouracil-based treatment? Eur. J. Cancer 36(1), 37-42 (2000). (Pubitemid 30035341)
7. Naguib FN, El Kouni MH, Cha S. Enyzmes of uracil catabolism in normal and neoplastic human tissues. Cancer Res. 45(11 Pt 1), 5405-5412 (1985). (Pubitemid 16200794)
8. Van Kuilenburg ABP. Dihydropyrimidine dehydrogenase and the effcacy and toxicity of 5-fuorouracil. Eur. J. Cancer 40(7), 939-950 (2004). (Pubitemid 38496249)
9. Etienne MC, Lagrange JL, Dassonville O et al. Population study of dihydropyrimidine dehydrogenase in cancer-patients. J. Clin. Oncol. 12(11), 2248-2253 (1994). (Pubitemid 24346691)
10. Lu ZH, Zhang RW, Diasio RB. Dihydropyrimidine dehydrogenase-activity in human peripheral-blood mononuclear-cells and liver-population characteristics, newly identifed defcient patients, and clinical implication in 5-fuorouracil chemotherapy. Cancer Res. 53(22), 5433-5438 (1993). (Pubitemid 23342163)
11. Boisdron-Celle M, Remaud G, Traore S et al. 5-fuorouracil-related severe toxicity: a comparison of different methods for the pretherapeutic detection of dihydropyrimidine dehydrogenase defciency. Cancer Lett. 249(2), 271-282 (2007). (Pubitemid 46452935)
12. Yang CG, Ciccolini J, Blesius A et al. DPD-based adaptive dosing of 5-FU in patients with head and neck cancer: impact on treatment effcacy and toxicity. Cancer. Chemother. Pharmacol. 67(1), 49-56 (2011).
13. Bakkeren JA, De Abreu RA, Sengers RC, Gabreels FJ, Maas JM, Renier WO. Elevated urine, blood and cerebrospinal fuid levels of uracil and thymine in a child with dihydrothymine dehydrogenase defciency. Clin. Chim. Acta 140(3), 247-256 (1984). (Pubitemid 14090775)
14. Berger R, Stoker-De Vries SA, Wadman SK et al. Dihydropyrimidine dehydrogenase defciency leading to thymine-uraciluria. An inborn error of pyrimidine metabolism. Clin. Chim. Acta 141(2-3), 227-234 (1984). (Pubitemid 14064036)
15. van Kuilenburg AB, Vreken P, Abeling NG et al. Genotype and phenotype in patients with dihydropyrimidine dehydrogenase defciency. Hum. Genet. 104(1), 1-9 (1999). (Pubitemid 29134634)
16. Wei X, Elizondo G, Sapone A et al. Characterization of the human dihydropyrimidine dehydrogenase gene. Genomics 51(3), 391-400 (1998). (Pubitemid 28413205)
17. Sherry ST, Ward MH, Kholodov M et al. dbSNP: the NCBI database of genetic variation. Nucleic Acids Res. 29(1), 308-311 (2001). (Pubitemid 32054478)
18. Santini J, milano G, Thyss A et al. 5-FU therapeutic monitoring with dose adjustment leads to an improved therapeutic index in head and neck-cancer. Br. J. Cancer 59(2), 287-290 (1989). (Pubitemid 19072735)
19. Magné N, Etienne-Grimaldi MC, Cals L et al. Dihydropyrimidine dehydrogenase activity and the IVS14 + 1G>A mutation in patients developing 5FU-related toxicity Br. J. Clin. Pharmacol. 64(2), 237-240 (2007). (Pubitemid 47063247)
20. van Kuilenburg AB, Baars JW, Meinsma R, Gennip AH. Lethal 5-fuorouracil toxicity associated with a novel mutation in the dihydropyrimidine dehydrogenase gene. Ann. Oncol. 14(2), 341-342 (2003). (Pubitemid 36305452)
21. van Kuilenburg ABP, Muller EW, Haasjes J et al. Lethal outcome of a patient with a complete dihydropyrimidine dehydrogenase (DPD) defciency after administration of 5-fuorouracil: frequency of the common IVS14 + 1G>A mutation causing DPD defciency Clin. Cancer Res. 7(5), 1149-1153 (2001). (Pubitemid 32708664)
22. Johnson MR, Diasio RB. Importance of dihydropyrimidine dehydrogenase (DPD) defciency in patients exhibiting toxicity following treatment with 5-fuorouracil. Adv. Enzyme Regul. 41, 151-157 (2001).
23. Milano G, Etienne MC, Pierrefte V, Barberi-Heyob M, Deporte-Fety R, Renée N. Dihydropyrimidine dehydrogenase defciency and fuorouracil-related toxicity. Br. J. Cancer 79, 627-630 (1999). (Pubitemid 29046246)
24. Largillier R, Etienne-Grimaldi MC, Formento JL et al. Pharmacogenetics of capecitabine in advanced breast cancer patients. Clin. Cancer. Res. 12(18), 5496-5502 (2006). (Pubitemid 44497266)
25. Ciccolini J, Mercier C, Evrard A et al. A rapid and inexpensive method for anticipating severe toxicity to fuorouracil and fuorouracil-based chemotherapy. Ther. Drug Monit. 8(5), 678-685 (2006). (Pubitemid 44564069)
26. Van Kuilenburg AB, Haasjes J, Richel DJ et al. Clinical implications of dihydropyrimidine dehydrogenase (DPD) defciency in patients with severe 5-fuorouracil-associated toxicity: identifcation of new mutations in the DPD gene. Clin. Cancer. Res. 6(12), 4705-4712 (2000). (Pubitemid 32110408)
27. Saif MW, Choma A, Salamone SJ, Chu E. Pharmacokinetically guided dose adjustment of 5-fuorouracil: a rational approach to improving therapeutic outcomes. J. Natl Cancer Inst. 101(22), 1543-1552 (2009).
28. Van Kuilenburg ABP, Meinsma R, Zonnenberg BA et al. Dihydropyrimidinase defciency and severe 5-fuorouracil toxicity. Clin. Cancer Res. 9(12), 4363-4367 (2003). (Pubitemid 37248392)
29. Lazar A, Mau-Holzmann UA, Kolb H, Reichenmiller HE, Riess O, Schomig E. Multiple organ failure due to 5-fuorouracil chemotherapy in a patient with a rare dihydropyrimidine dehydrogenase gene variant. Onkologie 27(6), 559-562 (2004). (Pubitemid 39664150)
30. Raida M, Schwabe W, Hausler P et al. Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5́-splice donor site of intron 14 in patients with severe 5-fuorouracil (5-FU)-related toxicity compared with controls. Clin. Cancer Res. 7(9), 2832-2839 (2001). (Pubitemid 32911393)
31. Seck K, Riemer S, Kates R et al. Analysis of the DPYD gene implicated in 5-fuorouracil catabolism in a cohort of Caucasian individuals. Clin. Cancer Res. 11(16), 5886-5892 (2005). (Pubitemid 41170317)
32. Wei XX, Mcleod HL, Mcmurrough J, Gonzalez FJ, Fernandezsalguero P. Molecular basis of the human dihydropyrimidine dehydrogenase defciency and 5-fuorouracil toxicity. J. Clin. Invest. 98(3), 610-615 (1996). (Pubitemid 26349163)
33. Vreken P, Vankuilenburg ABP, Meinsma R et al. A point mutation in an invariant splice donor site leads to exon skipping in two unrelated Dutch patients with dihydropyrimidine dehydrogenase defciency. J. Inherited Metabolic Dis. 19(5), 645-654
34. van Kuilenburg ABP, Meinsma R, Zoetekouw L, Gennip AHV. High prevalence of the IVS14 + 1G>A mutation in the dihydropyrimidine dehydrogenase gene of patients with severe 5-fuorouracil-associated toxicity Pharmacogenetics 12(7), 555-558 (2002). (Pubitemid 35177085)
35. Morel A, Boisdron-Celle M, Fey L et al. Clinical relevance of different dihydropyrimidine dehydrogenase gene single nucleotide polymorphisms on 5-fuorouracil tolerance. Mol. Cancer Ther. 5(11), 2895-2904 (2006). (Pubitemid 44849017)
36. Schwab M, Zanger UM, Marx C et al. Role of genetic and nongenetic factors for fuorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group. J. Clin. Oncol. 26(13), 2131-2138 (2008).
37. Johnson MR, Wang K, Diasio RB. Profound dihydropyrimidine dehydrogenase defciency resulting from a novel compound heterozygote genotype. Clin. Cancer Res. 8(3), 768-774 (2002). (Pubitemid 34742106)
38. Van Kuilenburg AB, Dobritzsch D, Meinsma R et al. Novel disease-causing mutations in the dihydropyrimidine dehydrogenase gene interpreted by ana lysis of the three-dimensional protein structure. Biochem. J. 364(Pt 1), 157-163 (2002). (Pubitemid 34538958)
39. Mattison LK, Johnson MR, Diasio RB. A comparative ana lysis of translated dihydropyrimidine dehydrogenase cDNA, conservation of functional domains and relevance to genetic polymorphisms. Pharmacogenetics 12(2), 133-144 (2002). (Pubitemid 34298917)
40. Gross E, Busse B, Riemenschneider M et al. Strong association of a common dihydropyrimidine dehydrogenase gene polymorphism with fuoropyrimidine-related toxicity in cancer patients. PLoS ONE 3 (12), e4003 (2008).
41. Loganayagam A, Arenas-Hernandez M, Fairbanks L, Ross P, Sanderson JD, Marinaki Am. The contribution of deleterious DPYD gene sequence variants to fuoropyrimidine toxicity in British cancer patients. Cancer Chemother. Pharmacol. 65(2), 403-406 (2010).
42. Amstutz U, Farese S, Aebi S, Largiadèr CR. Dihydropyrimidine dehydrogenase gene variation and severe 5-fuorouracil toxicity: a haplotype assessment. Pharmacogenomics 10(6), 931-944 (2009).
43. van Kuilenburg AB, Meijer J, Mul AN et al. Intragenic deletions and a deep intronic mutation affecting pre-mRNA splicing in the dihydropyrimidine dehydrogenase gene as novel mechanisms causing 5-fuorouracil toxicity Hum. Genet. 128(5), 529-538 (2010).
44. Savva-Bordalo J, Ramalho-Carvalho J, Pinheiro M et al. Promoter methylation and large intragenic rearrangements of DPYD are not implicated in severe toxicity to 5-fuorouracil-based chemotherapy in gastrointestinal cancer patients. BMC Cancer 10, 470 (2010).
45. Ticha I, Kleiblova P, Fidlerova J, Novotny J, Pohlreich P, Kleibl Z. Lack of large intragenic rearrangements in dihydropyrimidine dehydrogenase (DPYD) gene in fuoropyrimidine-treated patients with high-grade toxicity Cancer Chemother. Pharmacol. 64(3), 615-618 (2009).
46. Kleibl Z, Fidlerova J, Kleiblova P et al. Infuence of dihydropyrimidine dehydrogenase gene (DPYD) coding sequence variants on the development of fuoropyrimidine-related toxicity in patients with high-grade toxicity and patients with excellent tolerance of fuoropyrimidine-based chemotherapy. Neoplasma 56(4), 303-316 (2009).
47. Ben Fredj R, Gross E, Chouchen L et al. Mutational spectrum of dihydropyrimidine dehydrogenase gene (DPYD) in the Tunisian population. CR Biol. 330(10), 764-769 (2007). (Pubitemid 47457228)
48. Cho H, Park Y, Kang W, Kim J, Lee S. Thymidylate synthase (TYMS) and dihydropyrimidine dehydrogenase (DPYD) polymorphisms in the Korean population for prediction of 5-fuorouracil-associated toxicity. Ther. Drug Monit. 29(2), 190-196 (2007). (Pubitemid 46716185)
49. Maekawa K, Saeki M, Saito Y et al. Genetic variations and haplotype structures of the DPYD gene encoding dihydropyrimidine dehydrogenase in Japanese and their ethnic differences. J. Hum. Genet 52(10), 804-819 (2007). (Pubitemid 47512857)
50. Schroth W, Hamann U, Fasching PA et al. CYP2D6 polymorphisms as predictors of outcome in breast cancer patients treated with tamoxifen: expanded polymorphism coverage improves risk stratifcation. Clin. Cancer Res. 16(17), 4468-4477 (2010).
51. Steiner M, Seule M, Steiner B et al. 5-fuorouracil/irinotecan induced lethal toxicity as a result of a combined pharmacogenetic syndrome: report of a case. J. Clin. Path. 58(5), 553-555 (2005). (Pubitemid 40646882)
52. Hoskins JM, Goldberg RM, Qu PP, Ibrahim JG, Mcleod Hl. UGT1A1*28 genotype and irinotecan-induced neutropenia: Dose matters. J. Natl Cancer Inst. 99(17), 1290-1295 (2007). (Pubitemid 47394168)
53. Magne N, Pivot X, Etienne-Grimaldi MC et al. Impact of platinum complexes on dihydropyrimidine dehydrogenase activity in 5-fuorouracil-treated patients. Ann. Oncol. 14(8), 1329-1330 (2003). (Pubitemid 37039064)
54. Sobrero AF, Aschele C, Bertino JR. Fluorouracil in colorectal cancer-a tale of two drugs: implications for biochemical modulation. J. Clin. Oncol. 15(1), 368-381 (1997). (Pubitemid 27020595)
55. Walko CM, Lindley C. Capecitabine: a review. Clin. Therapeutics 27(1), 23-44 (2005). (Pubitemid 40347299)
56. Videnovic A, Semenov I, Chua-Adajar R et al. Capecitabine-induced multifocal leukoencephalopathy: a report of fve cases. Neurology 65(11), 1792-1794 (2005).
57. Fantini M, Gianni L, Tassinari D et al. Toxic encephalopathy in elderly patients during treatment with capecitabine: literature review and a case report. J. Oncol. Pharm. Prac. (2010).
58. Blasco H, Boisdron-Celle M, Bougnoux P et al. A well-tolerated 5-FU-based treatment subsequent to severe capecitabine-induced toxicity in a DPD-defcient patient. Br. J. Clin. Pharm. 65(6), 966-970 (2008). (Pubitemid 351677424)
59. Hsiao HH, Yang MY, Chang JG et al. Dihydropyrimidine dehydrogenase pharmacogenetics in the Taiwanese population. Cancer Chemother. Pharmacol. 53(5), 445-451(2004).
60. Wysocki PJ, Hutka M. Cardiotoxicity of 5-fuorouracil in a young colorectal cancer patient-case report and review of literature. Arch. Med. Sci. 5(2), 277-280 (2009).
61. Collie-Duguid ESR, Etienne MC, Milano G, Mcleod HL. Known variant DPYD alleles do not explain DPD defciency in cancer patients. Pharmacogenetics 10(3), 217-223 (2000). (Pubitemid 30242737)
62. Van Kuilenburg AB, Meinsma R, Zoetekouw L, Van Gennip AH. Increased risk of grade IV neutropenia after administration of 5-fuorouracil due to a dihydropyrimidine dehydrogenase defciency: high prevalence of the IVS14+1g>a mutation. Int. J. Cancer 101(3), 253-258 (2002). (Pubitemid 34970893)
63. Chansky K, Benedetti J, Macdonald JS. Differences in toxicity between men and women treated with 5-fuorouracil therapy for colorectal carcinoma. Cancer 103(6), 1165-1171 (2005). (Pubitemid 40328086)
64. Ezzeldin HH, Lee AM, Mattison LK, Diasio RB. Methylation of the DPYD promoter: an alternative mechanism for dihydropyrimidine dehydrogenase defciency in cancer patients. Clin. Cancer Res. 11(24), 8699-8705 (2005). (Pubitemid 43005919)
65. Yu J, Mcleod HL, Ezzeldin HH, Diasio RB. Methylation of the DPYD promoter and dihydropyrimidine dehydrogenase defciency Clin. Cancer Res. 12(12), 3864; author reply 3864 (2006). (Pubitemid 44000269)
66. Amstutz U, Farese S, Aebi S, Largiadèr CR. Hypermethylation of the DPYD promoter region is not a major predictor of severe toxicity in 5-fuorouracil based chemotherapy J. Exp. Clin. Cancer Res. 27, 54 (2008).
67. Amstutz U, Andrey-Zurcher G, Suciu D, Jaggi R, Haberle J, Largiader CR. Sequence capture and next-generation resequencing of multiple tagged nucleic acid samples for mutation screening of urea cycle disorders. Clin. Chem. 57(1), 102-111 (2011).
68. Chou LS, Liu CS, Boese B, Zhang X, Mao R. DNA sequence capture and enrichment by microarray followed by next-generation sequencing for targeted resequencing: neurofbromatosis type 1 gene as a model. Clin. Chem. 56(10), 62-72 (2010).
69. Ten Bosch JR, Grody WW. Keeping up with the next generation: massively parallel sequencing in clinical diagnostics. J. Mol. Diagn. 10(6), 484-492 (2008).
70. Vasta V, Ng SB, Turner Eh, Shendure J, Hahn SH. Next generation sequence ana lysis for mitochondrial disorders. Genome Med. 1(10), 100 (2009).
71. Zhang X, Li L, Fourie J, Davie JR, Guarcello V, Diasio RB. The role of Sp1 and Sp3 in the constitutive DPYD gene expression. Biochim. Biophys. Acta 1759(5), 247-256 (2006). (Pubitemid 44041696)
72. Scartozzi M, Maccaroni E, Giampieri R et al 5-fuorouracil pharmacogenomics: still rocking after all these years? Pharmacogenomics 12(2), 251-265 (2011).
73. Ciccolini J, Gross E, Dahan L, Lacarelle B, Mercier C. Routine dihydropyrimidine dehydrogenase testing for anticipating 5-fuorouracil-related severe toxicities: hype or hope? Clin. Col. Cancer 9(4), 224-228 (2010).
74. Longley DB, Harkin DP, Johnston PG. 5-fuorouracil: mechanisms of action and clinical strategies. Nat. Rev. Cancer 3(5), 330-338 (2003). (Pubitemid 37328853)
75. Gross E, Ullrich T, Seck K et al. Detailed ana lysis of fve mutations in dihydropyrimidine dehydrogenase detected in cancer patients with 5-fuorouracil-related side effects. Hum. Mutat. 22(6), 498 (2003).
76. Van Kuilenburg AB, Meinsma R, Beke E et al. Identifcation of three novel mutations in the dihydropyrimidine dehydrogenase gene associated with altered pre-mRNA splicing or protein function. Biol. Chem. 386(4), 319-324 (2005). (Pubitemid 41447594)
77. Johnson MR, Wang K, Diasio RB. Profound dihydropyrimidine dehydrogenase defciency resulting from a novel compound heterozygote genotype. Clin. Cancer Res. 8(3), 768-774 (2002). (Pubitemid 34742106)
78. Van Kuilenburg AB, Vreken P, Beex LV et al. Heterozygosity for a point mutation in an invariant splice donor site of dihydropyrimidine dehydrogenase and severe 5-fuorouracil related toxicity. Eur. J. Cancer 33(13), 2258-2264 (1997). (Pubitemid 28123420)
79. Boige V, Mendiboure J, Pignon JP et al. Pharmacogenetic assessment of toxicity and outcome in patients with metastatic colorectal cancer treated with LV5FU2, FOLFOX, and FOLFIRI: FFCD 2000-05. J. Clin. Oncol. 28(15), 2556-2564 (2010).
80. Johnson MR, Hageboutros A, Wang K, High L, Smith JB, Diasio RB. Life-threatening toxicity in a dihydropyrimidine dehydrogenase-defcient patient after treatment with topical 5-fuorouracil. Clin. Cancer Res. 5(8), 2006-2011 (1999). (Pubitemid 29399251)
81. Ezzeldin H, Johnson MR, Okamoto Y, Diasio R. Denaturing high performance liquid chromatography ana lysis of the DPYD gene in patients with lethal 5-fuorouracil toxicity. Clin. Cancer Res. 9(8), 3021-3028 (2003). (Pubitemid 36993262)
82. Ridge SA, Sludden J, Brown O et al. Dihydropyrimidine dehydrogenase pharmacogenetics in Caucasian subjects. Br. J. Clin. Pharmacol. 46(2), 151-156 (1998). (Pubitemid 28342786)
83. Largiadèr CR, Amstutz U, Froehlich TK et al. The dihydropyrimidine dehydrogenase gene as a major predictor of severe 5-fuorouracil toxicity: a classic reborn? Presented at: CSHL Meeting on Pharmacogenomics and Personalized Medicine. Cold Spring Harbor, NY, USA, 17-20 November (2010).